XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Share Option Plans and ESPP (Tables)
 6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]  
Schedule of Stock Option Plans
A summary of the status of the Company’s option plans as of June 30, 2021 and changes during the period then ended is presented below:
Six months ended June 30, 2021
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year9,220,326 $26.21 
Granted386,909 154.71 
Exercised(798,511)20.75 
Forfeited and canceled(88,627)58.14 
Outstanding as of June 30, 20218,720,097 $32.09 
Exercisable options5,101,756 $18.81 
Schedule of RSUs and PSUs A summary of the status of the Company’s RSUs and PSUs as of June 30, 2021 and changes during the period then ended is presented below.
Six months ended June 30, 2021
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year4,466,151 $54.06 
Granted552,095 140.94 
Vested(491,160)49.18 
Forfeited and cancelled(40,380)83.60 
Unvested as of June 30, 2021 (1)4,486,706 65.02 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of June 30, 2021, in accordance with ASC 718 as follows:
 June 30, 2021
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
2,703,852 $48.16 $130,218 
108,113 69.37 7,500 
17,712 84.68 1,500 
94,813 $114.26 10,833 
2,924,490 $150,051 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: 
Six months ended June 30,Year ended December 31,
2020
20212020
UnauditedAudited
Stock Option Plans
Expected term (years)
5.50-6.00
5.50-6.25
5.50-6
Expected volatility
60%-62%
54%-56%
54%-56%
Risk-free interest rate
0.85%-1.02%
0.39%-0.86%
0.30%-0.86%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility54 %47 %
47%-66%
Risk-free interest rate0.09 %1.57 %
0.17%-1.57%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2021 and 2020 and the year ended December 31, 2020 was:
Three months ended June 30,Six months ended June 30,Year ended December 31,
2020
2021202020212020
UnauditedUnauditedAudited
Cost of revenues$827 $559 $1,560 $1,149 $2,221 
Research, development and clinical trials8,505 3,779 13,629 7,173 18,125 
Sales and marketing6,429 4,769 10,900 8,385 17,672 
General and administrative12,120 9,663 20,655 18,620 37,703 
Total share-based compensation expense$27,881 $18,770 $46,744 $35,327 $75,721